BioCryst Pharmaceuticals

Three blocks displaying from left to right a person a handshake and another person
Biotech

BioCryst inks $700M Astria deal to rival Takeda in rare disease

The takeover will give the rare disease specialist control of a phase 3 challenger to Takeda’s hereditary angioedema therapy Takhzyro.
Nick Paul Taylor Oct 14, 2025 10:30am
dusk parachute

Novo Nordisk nominates CEO successor—Chutes & Ladders

Aug 1, 2025 8:30am
Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

BMS vet answers Foghorn’s call for CBO—Chutes & Ladders

Sep 6, 2024 8:30am
throw away trash garbage bin

45 days later, BioCryst abandons another drug, citing competition

Dec 15, 2022 10:29am
relay race baton pass

BioCryst leaves ultra-rare disease efforts in hands of peers

Nov 1, 2022 10:00am
FDA

BioCryst's voluntary pause turns into partial FDA hold

May 5, 2022 11:11am